Compare TG Therapeutics Inc (TGTX) vs Unilever plc (UL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Unilever plc — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while Unilever plc trades at $62.22 (market cap $131.63B). The key difference: Unilever plc is far larger — about 16.1× TG Therapeutics Inc's market cap, and Unilever plc pays a 3.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Unilever plc for 112 Days on average.
| TGTX | UL | |
|---|---|---|
Market Cap | $8.16B | $131.63B |
Volume | 1,735,121 | 2,978,741 |
Sector | Health | Consumer Staples |
52-Week High | $59.06 | $74.59 |
52-Week Low | $26.94 | $55.05 |
Typical Hold Time | 16 Days | 112 Days |
Enterprise Value | $8.37B | $156.65B |
Dividend Yield | — | 3.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Unilever (UL) trades at $62.26, up 2.1% today, with a bullish technical signal from moving averages. The company shows strong profitability with 18.32% net income margin and 54.56% ROE, though recent earnings have missed expectations in four consecutive quarters. Unilever is undergoing strategic transformation through its $65 billion food business merger with McCormick while focusing on beauty and personal care segments.
The outlook balances strong emerging market exposure and margin improvement against execution risks from the McCormick deal and competitive pressures. Analyst sentiment is mixed with 24% buy ratings, creating opportunity if restructuring delivers promised returns, though regulatory scrutiny and earnings consistency remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →
